| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000021337 |
| Receipt No. | R000024339 |
| Official scientific title of the study | Safety and efficacy of scallop-plasmalogen on patients with primary insomnia:double-blind crossover trial with Polysomnography |
| Date of disclosure of the study information | 2016/03/04 |
| Last modified on | 2017/09/06 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | Safety and efficacy of scallop-plasmalogen on patients with primary insomnia:double-blind crossover trial with Polysomnography
|
|
| Title of the study (Brief title) | Safety and efficacy of scallop-plasmalogen on patients with primary insomnia | |
| Region |
|
|
| Condition | ||
| Condition | primary insomnia | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To polysomnographically evaluate the effects of improving sleep quality in patients with insomnia by scallop-plasmalogen intake |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Improvement of wake after sleep onset |
| Key secondary outcomes | Improvement of sleep efficiency and sleep latency |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Cross-over |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Stage 1
Test food containing 0.5 mg scallop-plasmalogen administered, twice a day for 2 weeks Stage 2 Placebo administered, twice a day for 2 weeks |
|
| Interventions/Control_2 | Stage 1
Placebo administered, twice a day for 2 weeks Stage 2 Test food containing 0.5 mg scallop-plasmalogen administered, twice a day for 2 weeks |
|
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1.Informed consent from patients or proxies
2.Male or female patients aged 25 through 65 years with primary insomnia involving hypnagogic disorder or awakening that lasts for more than three months 3.Patients who are not taking sleeping medicine continuously or are able to stop taking one-shot-medicine within 14 days of starting examination 4.Patients judged eligible for this study by the investigator |
|||
| Key exclusion criteria | 1.Patients with depression, history of severe mental or physical illness, or sleep disorder other than insomnia (sleep apnea syndrome, restless legs syndrome)
2.Patients with scallop allergy 3.Patients judged ineligible for this study by the investigator |
|||
| Target sample size | 16 | |||
| Research contact person | |
| Name of lead principal investigator | Kazuyuki Saito |
| Organization | BOOCS Clinic Fukuoka |
| Division name | Hospital director |
| Address | 6-18 Tenya-machi, Hakata-ku, Fukuoka |
| TEL | 092-283-6852 |
| saito@tkz.bbiq.jp | |
| Public contact | |
| Name of contact person | Kyoko Tsuchihashi |
| Organization | BOOCS Clinic Fukuoka |
| Division name | general affairs division |
| Address | 6-18 Tenya-machi, Hakata-ku, Fukuoka |
| TEL | 092-283-6852 |
| Homepage URL | |
| kyoko@boocsclinic.com | |
| Sponsor | |
| Institute | BOOCS Clinic Fukuoka |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Japanese Plasmalogen Society |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024339 |